Rani Therapeutics Holdings, Inc.
RANI
$0.84
-$0.03-3.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 893.02% | 42.12% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 893.02% | 42.12% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 893.02% | 42.12% | -- | -- |
| SG&A Expenses | 10.38% | -12.98% | -6.87% | -28.27% | -21.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.30% | -17.55% | -18.55% | -38.49% | -16.12% |
| Operating Income | 15.96% | 30.58% | 24.09% | 38.49% | 16.12% |
| Income Before Tax | 24.97% | 37.08% | 42.28% | 37.79% | 15.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 24.97% | 37.08% | 42.28% | 37.79% | 15.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -77.27% | -82.06% | -118.17% | -57.87% | -30.87% |
| Net Income | -10.45% | 3.18% | -15.18% | 20.21% | 1.66% |
| EBIT | 15.96% | 30.58% | 24.09% | 38.49% | 16.12% |
| EBITDA | 15.48% | 30.47% | 23.95% | 39.05% | 16.33% |
| EPS Basic | 78.43% | 82.00% | 43.12% | 50.47% | 29.17% |
| Normalized Basic EPS | 66.72% | 69.89% | -341.52% | 24.64% | 0.44% |
| EPS Diluted | 78.43% | 82.00% | 43.12% | 50.47% | 29.17% |
| Normalized Diluted EPS | 66.72% | 69.89% | -341.52% | 24.64% | 0.44% |
| Average Basic Shares Outstanding | 412.20% | 438.27% | 102.50% | 61.06% | 38.82% |
| Average Diluted Shares Outstanding | 412.20% | 438.27% | 102.50% | 61.06% | 38.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |